[1]董胜鉴,黄丽丽,李树锦.肺腺癌患者血清中miR-498，miR-339-5p和miR-210-3p水平表达的临床诊断价值[J].现代检验医学杂志,2022,37(02):58-60.[doi:10.3969/j.issn.1671-7414.2022.02.012]
　DONG Sheng- jian,HUANG Li- li,LI Shu -jin.Clinical Diagnostic Value Expressed at miR-498, miR-339-5p and miR-210-3p Levels in Serum in Patients with Lung Adenocarcinoma[J].Journal of Modern Laboratory Medicine,2022,37(02):58-60.[doi:10.3969/j.issn.1671-7414.2022.02.012]
点击复制

肺腺癌患者血清中miR-498，miR-339-5p和miR-210-3p水平表达的临床诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
58-60
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Clinical Diagnostic Value Expressed at miR-498, miR-339-5p and miR-210-3p Levels in Serum in Patients with Lung Adenocarcinoma
文章编号:
1671-7414（2022）02-058-03
作者:
董胜鉴; 黄丽丽; 李树锦
（合肥市第二人民医院检验科，合肥 230001）
Author(s):
DONG Sheng- jian ;  HUANG Li- li;  LI Shu -jin
(Department of Clinical Laboratory, the Second People’s Hospital of Hefei City，Hefei 230001，China)
关键词:
肺腺癌; miR-498; miR-339-5p; miR-210-3p
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.012
文献标志码:
A
摘要:
目的　研究肺腺癌（lung adenocarcinoma, LA）患者血清中微核糖核酸（miRNA）在肺腺癌患者及正常人群组血清中的表达水平，分析其在肺腺癌诊断中的临床价值。方法 　收集60 例肺腺癌及40 例正常人群血清，通过实时荧光定量聚合酶链反应（quantitative real time PCR,qRT PCR）检测各组血清miR-498, miR-339-5p 和 miR-210-3p 的表达情况。统计分析各组miRNA 的表达差异以及单个miRNA 在肺腺癌诊断中的价值，进一步用统计学方法分析三者联合检测的诊断价值。结果　相比正常人群，肺腺癌患者血清中miR-210-3p 表达增加（6.41±1.85 vs 4.52±1.45），miR-498（2.09±0.88vs 3.01±0.69）和miR-339-5p（0.8±0.53 vs 1.24±0.58）表达下降，差异有统计学意义(t=4.72, 1.34, 2.75，均P ＜ 0.05）。受试者工作特征曲线下面积（AUC）分析结果显示，miR-498 ，miR-339-5p 和miR-210-3p 的AUC 分别为 0.788（95%CI0.695 ～ 0.864），0.715（95%CI 0.616 ～ 0.801）和0.799（95%CI 0.707 ～ 0.872 ）；三者联合检测在肺腺癌诊断中AUC 值为0.902（95%CI 0.826 ～ 0.952），三者联合检测优于单个miRNA 的检测，差异有统计学意义（t=14.09 ～ 18.65,均P ＜ 0.05）。结论　miR-498, miR-339-5p 和miR-210-3p 在肺腺癌患者血清中的表达情况改变，对肺腺癌具有一定的临床诊断价值。
Abstract:
Objective　The expression level of micro ribonucleic acid（miRNA）in serum in patients with lung adenocarcinoma(LA) and in the serum of normal population groups was analyzed, and its clinical value in the diagnosis of lung adenocarcinoma was analyzed. Methods　Serums from 60 cases of LA and 40 normal physical examination subjects were collected, and the expressions of miR-498,miR-339-5p and miR-210-3p in each groups were detected by real time fluorescence quantitative PCR. The expression differences of miRNA in each group and the value of single serum miRNA in the diagnosis of lung adenocarcinoma were statistically analyzed, and the diagnostic value of three miRNA combined detection was further analyzed by statistical methods. Results　Compared with the normal population, the expression of miR-210-3p（6.41±1.85 vs 4.52±1.45）was increased in the serum of patients with lung adenocarcinoma, and the expressions of miR-498（2.09±0.88 vs 3.01±0.69） and miR-339-5p （0.8±0.53 vs 1.24±0.58）were decreased, and the differences were statistically significant (t=4.72,1.34,2.75, all P ＜ 0.05).Area under the receiver operating characteristic curve(AUC) analysis results showed that the AUC of miR-498 ,miR-339-5p and miR-210-3p was 0.788（95%CI 0.695 ～ 0.864）,0.715（95%CI 0.616 ～ 0.801）and 0.799 （95%CI 0.707 ～ 0.872）, respectively. In the diagnosis of lung adenocarcinoma, the three combined was 0.902（95%CI 0.826 ～ 0.952）, which was better than any of three miRNAs（(χ2=14.09 ～ 18.65, all P ＜ 0.05）. Conclution　The changes in the expression of miR 498, miR 339 5p and miR 210 3p in the serum of patients with LA can be used as a certain clinical value in the diagnosis of lung adenocarcinoma.

参考文献/References:

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2020[J]. CA-A Cancer Journal for Clinicians, 2020, 70(1): 7 30.
[2] SCAFOGLIO C R, VILLEGAS B, ABDELHADY G, et al. Sodium glucose transporter 2 is a diagnostic and therapeutic target for early stage lung adenocarcinoma[ J]. Science Translational Medicine, 2018, 10(467): aat5933.
[3] DE KONING H J, VAN DER AALST C M, DE JONG P A, et al. Reduced lung cancer mortality with volume CT screening in a randomized trial[J]. The New England Journal of Medicine, 2020, 382(6): 503 -513.
[4] ZAMAY T N, ZAMAY G S, KOLOVSKAYA O S, et al. Current and prospective protein biomarkers of lung cancer[J]. Cancers, 2017, 9(11): 155.
[5] CHEN Liang, HEIKKINEN L, WANG Changliang, et al. Trends in the development of miRNA bioinformatics tools[J]. Briefings in Bioinformatics, 2019, 20(5): 1836- 1852.
[6] JIN Xiance, CHEN Yanfan, CHEN Hanbin, et al. Evaluation of tumor derived exosomal miRNA as potential diagnostic biomarkers for early-stage non small cell lung cancer using next generation sequencing[J]. Clinical Cancer Research, 2017, 23(17): 5311-5319.
[7] PU Mengfan,LI Chenggang,QI Xinming,et al.MiR 1254 suppresses HO 1 expression through seed regiondependent silencing and non seed interaction with TFAP2A transcript to attenuate NSCLC growth[J]. PLoS Genetics, 2017, 13(7): e1006896.
[8] TONG Yusuo, WANG Xiaowei, ZHOU Xilei, et al. Identification of the long non coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma[J]. Molecular Cancer, 2015, 14(1): 3.
[9] OSIPOVA J, FISCHER D C, DANGWAL S A, et al. Diabetes associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross sectional cohort study[J]. Journal of Clinical Endocrinology & Metabolism, 2014, 99(9): E1661-E1665.
[10] NAVICKAS R, GAL D, LAUCEVICIUS A A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review[J]. Cardiovascular Research, 2016, 111(4): 322 -337.
[11] RUPAIMOOLE R, SLACK F J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nature Reviews Drug Discovery, 2017, 16(3): 203-221.
[12] LIU Ruonan, LIU Fenghua, LI Lei, et al. MiR- 498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells[J]. Biomedicine & Pharmacotherapy, 2015, 72:52-57.
[13] LUO Aiping, ZHOU Xuantong, SHI Xing, et al. Exosome derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma[J]. Oncogene, 2019, 38(25): 4990-5006.
[14] WITLIK W, KARBOWNIK M S, SUWALSKI M, et al. MiR 30a 5p together with miR-210-3p as a promising biomarker for non small cell lung cancer: a preliminary study[J]. Cancer Biomarkers, 2018, 21(2): 479 -488.
[15] XIE Songping, LIU Gaoli, HUANG Jie, et al. MiR 210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase like 4[J]. Journal of Cellular Physiology, 2019, 234(8): 14050-14057.

相似文献/References:

[1]刘　欣,张欢欢,关　平,等.肺腺癌细胞中长链非编码 RNA- ARAP1-AS1 表达模式及其生物学特征[J].现代检验医学杂志,2021,36(03):38.[doi:10.3969/j.issn.1671-7414.2021.03.009]
　LIU Xin,ZHANG Huan-huan,GUAN Ping,et al.Expression Pattern and Biological Characteristics of ARAP1-AS1 in LungAdenocarcinoma Cells[J].Journal of Modern Laboratory Medicine,2021,36(02):38.[doi:10.3969/j.issn.1671-7414.2021.03.009]
[2]王利民,刘　锴.TUBA1C促进人肺腺癌细胞系增殖和迁移的机制研究[J].现代检验医学杂志,2021,36(04):74.[doi:10.3969/j.issn.1671-7414.2021.04.016]
　WANG Li-min,LIU Kai.Study on the Mechanism of TUBA1C Promoting Proliferation and Migrationof Lung Adenocarcinoma Cells[J].Journal of Modern Laboratory Medicine,2021,36(02):74.[doi:10.3969/j.issn.1671-7414.2021.04.016]
[3]胡艳正,牛彦杰,石鹏飞.长链非编码RNA LINC00222对肺腺癌细胞增殖、迁移、侵袭和凋亡的影响及作用机制的研究[J].现代检验医学杂志,2021,36(05):16.[doi:10.3969/j.issn.1671-7414.2021.05.004]
　HU Yan-zheng,NIU Yan-jie,SHI Peng-fei.Effect of Long Non Coding RNA LINC00222 on Proliferation, Migration,Invasion and Apoptosis of Lung Adenocarcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(02):16.[doi:10.3969/j.issn.1671-7414.2021.05.004]
[4]鲍培龙,徐月亮,王孝彬.miR-153对肺腺癌细胞增殖、侵袭、迁移和凋亡的影响及机制研究[J].现代检验医学杂志,2022,37(01):107.[doi:10.3969/j.issn.1671-7414.2022.01.022]
　BAO Pei-long,XU Yue-liang,WANG Xiao-bin.Effects of miR-153 on Proliferation, Invasion, Metastasis and Apoptosis of Lung Adenocarcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(02):107.[doi:10.3969/j.issn.1671-7414.2022.01.022]
[5]苗 毅a,杨淑梅a,王 晶b,等.肺腺癌组织中MCM4 的表达及其与预后、免疫微环境的相关性分析[J].现代检验医学杂志,2023,38(05):115.[doi:10.3969/j.issn.1671-7414.2023.05.022]
　MIAO Yia,YANG Shumeia,WANG Jingb,et al.Expression of MCM4 in Lung Adenocarcinoma and Its Correlation with Prognosis and Immune Microenvironment[J].Journal of Modern Laboratory Medicine,2023,38(02):115.[doi:10.3969/j.issn.1671-7414.2023.05.022]

备注/Memo

备注/Memo:
作者简介：董胜鉴（1974-），男，硕士，主管检验师，研究方向：医学免疫检验 ，E- mail:969717828@qq.com。
更新日期/Last Update: 1900-01-01